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Abstract
Transcellular propagation of tau aggregates may underlie the progression of pathology in 
Alzheimer’s disease (AD) and other tauopathies. Braak Staging (B1, B2, B3) is based on phospho-
tau accumulation within connected brain regions: entorhinal cortex (B1); hippocampus/limbic 
system (B2); and frontal and parietal lobes (B3). We previously developed a specific and sensitive 
assay that uses flow cytometry to quantify seeding activity based on fluorescence resonance 
energy transfer (FRET) in cells that stably express tau reporter proteins. In a tauopathy mouse 
model, we have detected seeding activity far in advance of histopathological changes. It remains 
unknown whether individuals with AD also develop seeding activity prior to accumulation of 
phospho-tau. We measured tau seeding activity across four brain regions (hippocampus, frontal 
lobe, parietal lobe, and cerebellum) in 104 fresh-frozen human AD brain samples from all Braak 
stages. We observed widespread seeding activity, notably in regions predicted to be free of 
phospho-tau deposition, and in detergent-insoluble fractions that lacked tau detectable by ELISA. 
Seeding activity correlated positively with Braak stage and negatively with MMSE. Our results are 
consistent with early transcellular propagation of tau seeds that triggers subsequent development 
of neuropathology. The FRET-based seeding assay may also complement standard 
neuropathological classification of tauopathies.
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INTRODUCTION
Alzheimer’s disease (AD) is characterized by learning and memory deficits and brain 
deposition of extracellular amyloid beta plaques and intracellular neurofibrillary tangles. In 
comparison to amyloid beta plaque load, tau accumulation better correlates with cognitive 
disturbances [3, 18, 28, 35], suggesting a fundamental role in neurodegeneration. The 
precise toxic form(s) of tau is unknown, but evidence suggests that transcellular propagation 
of tau aggregates, or seeds, could underlie disease progression [12, 13, 16, 19, 25, 29, 37]. 
Indeed, we and others have found that tau has essential prion properties [11, 12, 31]. The 
prion model predicts that tau seeds escape one neuron, are internalized by another, and serve 
as a template to convert native tau monomer into an ordered assembly [8, 12, 15, 20, 24, 31]. 
In prior work, we have hypothesized that transcellular propagation of tau seeding activity 
underlies the pattern of neuropathology in tauopathies such as AD [16, 32].
Tau pathology in AD develops progressively in synaptically connected brain regions. This 
forms the basis of Braak Staging [6, 7, 30, 34, 40], a well-established method that scores 
accumulation of phospho-tau based on AT8 antibody staining of specific brain regions [5]. 
While Braak staging has proved very useful, variance in staining and analysis adds a 
subjective aspect to the diagnosis of AD and other tauopathies. Furthermore, these methods 
are bounded by the detection limits of immunohistochemistry, while more sensitive methods 
could highlight earlier or more widespread abnormalities.
To quantify tau seeding activity we previously developed a cellular biosensor assay [21]. 
This is based on stable expression of tau repeat domain (RD) containing a single disease-
associated mutation (P301S) that is fused to cyan or yellow fluorescent protein (CFP or 
YFP). Exogenous tau aggregate seeds delivered to the cell interior with cationic lipids 
(Lipofectamine) trigger aggregation of intracellular RD-CFP/YFP by acting as a 
conformational template. The close approximation of CFP and YFP within an aggregate 
results in fluorescence resonance energy transfer (FRET) that is quantified by flow 
cytometry. This enables determination of tau aggregate seed “titer” over 3 orders of 
magnitude. We have not observed cross-reactivity with other amyloid proteins in the seeding 
assay [21, 31], and immunodepletion with an anti-tau antibody eliminates seeding activity 
from samples [21, 38]. Thus the assay appears highly sensitive and specific.
We have previously determined that aged, healthy human brains and tau knockout mice lack 
tau seeding activity [21]. By contrast, tau seeding activity progressively increases with age 
in the PS19 tauopathy mouse model (which expresses 1N,4R tau containing the P301S 
mutation), and anticipates neuropathological changes (AT8, MC1, and thioflavin staining) 
by many months [21]. These results are consistent with the idea that tau seeding triggers 
subsequent development of neuropathology. However, it is unknown whether a similar 
process might occur in AD. To test this prediction, we have measured tau seeding activity in 
fresh-frozen human brain specimens from multiple brain regions, across all Braak stages. 
We correlated seeding activity with Braak stage, clinical parameters, and tau biochemistry.
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MATERIALS & METHODS
Cell culture
HEK 293T cells were grown in DMEM (Gibco) supplemented with 10% fetal bovine serum 
(Sigma-Aldrich), 1% penicillin/streptomycin (Gibco), and 1% GlutaMax (Gibco). Cells 
were cultured at 37 °C with 5% CO2 in a humidified incubator.
Brain Tissue
We analyzed fresh-frozen specimens from brains that were previously categorized by 
qualified neuropathologists (C.L.W., N.J.C., P.T.N.). 40 subjects were staged according to 
Braak criteria as B1, B2, or B3 (defined as Braak I-II, Braak III-IV, or Braak V-VI, 
respectively). Subjects were diagnosed using standard tau histological measures (described 
below) and the 2012 criteria specified by the National Institute on Aging and the 
Alzheimer’s Association [5, 22]. Samples consisted of grey matter obtained from four 
distinct brain regions (hippocampus, frontal lobe (Brodmann Areas 8/9), parietal lobe 
(Brodmann Areas 39/40), or cerebellum) typically affected differentially with tau pathology 
through AD progression. Negative control tissue was obtained from individuals with 
psychiatric disturbance, or diagnosed with Huntington’s disease. In total, 126 brain 
specimens were analyzed.
Sample preparation
Fresh-frozen brain tissues were suspended in TBS containing EDTA-free cOmplete protease 
inhibitors (Roche) such that the total concentration was 10% w/vol. Samples were 
homogenized at 75 watts with pulsing using a probe sonicator (Omni International) for 15 
min on ice in a hood. Between each sample, we washed the probe with three isopropanol 
and distilled water rinses to prevent cross-contamination. Lysates were centrifuged at 23,000 
× g for 15 min, and the supernatant was retained (total fraction). Protein concentration was 
measured with BCA (Pierce) and normalized between all samples at 2 µg/µl. Fractions were 
aliquoted and stored at −80 °C until further use to avoid multiple freeze/thaw cycles.
Biochemical extraction
Biochemical extraction was performed as described previously [10]. Total fractions 
(described above) were centrifuged at 100,000 × g for 60 min at 4 °C, and the supernatant 
was collected (soluble fraction). Pellets were resuspended in 1% sarkosyl, incubated for 30 
min at room temperature with shaking, and centrifuged again at 100,000 × g for 60 min at 
4 °C. The resultant pellet was resuspended in TBS (insoluble fraction) [9]. Soluble and 
insoluble tau fractions were standardized by volume for ELISA and seeding assays.
Tau ELISA
A total tau “sandwich” ELISA was performed as described previously [1]. All antibodies 
were kindly provided by Dr. Peter Davies (Albert Einstein College of Medicine). 96 well 
round-bottom plates (Corning) were coated for 48 hours at 4 °C with DA-31 (aa 150–190) 
diluted in sodium bicarbonate buffer (6 µg/mL). Plates were rinsed with PBS 3 times, 
blocked for 2 hours at room temperature with Starting Block (Pierce), and rinsed with PBS 5 
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additional times. Total (1 µL), soluble (1 µL), and insoluble (0.3 µL) fractions were diluted 
in SuperBlock solution (Pierce; 20% SuperBlock, diluted in TBS), and 50 µL sample was 
added per well. DA-9 (aa 102–150) was conjugated to HRP using the Lighting-Link HRP 
Conjugation Kit (Innova Biosciences), diluted 1:50 in SuperBlock solution, and 50 µL was 
added per well (15 µg/mL). Sample + detection antibody complexes were incubated 
overnight at 4 °C. Plates were washed with PBS 9 times with a 15 sec incubation between 
each wash, and 75 µL 1-Step Ultra TMB Substrate Solution (Pierce) was added. Plates were 
developed for 30 min, and the reaction was quenched with 2M sulfuric acid. Absorbance 
was measured at 450 nm using an Epoch plate reader (BioTek). Each plate contained a 
standard curve, and all samples were run in triplicate.
Biochemical Quantification
Tau concentration was calculated using GraphPad Prism software. Standard curves were 
made using 2N,4R recombinant protein (rPeptide) ranging from 15.6 to 1000 pg/mL and 
were fitted using the sigmoidal, 4PL, X=log(concentration) nonlinear regression model. 
Samples were diluted so that concentrations fell on the linear portion of the standard curve.
Tau Seeding
Tau seeding activity was quantified as detailed previously [17, 21]. HEK 293T cells stably 
expressing the aggregation-prone repeat domain (RD) of tau containing the disease-
associated P301S mutation tagged to either CFP or YFP were transduced with human brain 
homogenates. At 60–65% confluency, transduction complexes consisting of lysate (either 20 
µg total, 2 µl soluble, or 5 µl insoluble fraction), Opti-MEM (Gibco), and Lipofectamine 
2000 (Invitrogen) were added to cells. Following treatment, cells were incubated for 24 hr 
prior to harvesting for FRET flow cytometry. Prior to FRET flow cytometry, we always 
confirmed visible RD-CFP/YFP inclusions in positive wells. Standardized seeding activity, 
reported here, is a fold change over background level of biosensor cells treated with empty 
liposomes, which is arbitrarily set at 1% positivity in the FRET gate.
FRET Flow Cytometry
FRET flow cytometry was performed as described previously [17, 21]. Following 24 hr 
treatment, cells were trypsinized, centrifuged, and fixed in 2% paraformaldehyde (Electron 
Microscopy Sciences). Cells were resuspended in flow cytometry buffer (HBSS, PBS, 1% 
FBS, and 1 mM EDTA) and analyzed using the MACSQuant VYB flow cytometer (Miltenyi 
Biotec). CFP, YFP, and FRET signals were detected with the following settings: CFP (405 
laser; 450/50 filter), YFP (488 laser; 525/50 filter), FRET (405 laser; 525/50 filter). Samples 
were run in quadruplicate, and 15,000–20,000 singlets were captured per well.
Flow Cytometry Analysis
FlowJo v10 software was used for analysis. Gating strategy was similar to that described 
previously [17, 21]. CFP and YFP spillover into the FRET channel were excluded using 
compensation and the “False FRET” gate. Empty liposome-treated cells were used as the 
baseline for background seeding, and FRET-positive events were identified from a FRET vs. 
CFP bivariate plot. The median fluorescence intensity (MFI) of FRET-positive events was 
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recorded. Integrated FRET Density (IFD; the product of percent cells FRET-positive and 
MFI) is presented here. This integrates the amount of seeding per population of cells with 
the degree of seeding within a positive cell.
Confocal Microscopy
All cells were grown and treated on microslides. Cells were fixed with 4% 
paraformaldehyde, and confocal images were obtained with a Zeiss LSM 780 Inverted 
confocal/multiphoton microscope.
Heat Map
Heat maps were generated using MATLAB software (MathWorks). The Integrated FRET 
Density values were log-transformed and colored on a red scale. Values less than 1.5-fold 
above untreated controls (non-significant levels) are shaded with light blue. The remaining 
values are shaded from light-to-dark blue on a continuum, with the latter representing the 
highest fold increase in IFD. If no sample was available, the rectangle is filled with grey 
dots.
Immunohistochemistry
Paraffin sections were cut at 4 µm thickness on a rotary microtome, mounted on positively 
charged glass slides, and air-dried overnight. Sections were deparaffinized in xylene and 
alcohol, pretreated in 98% formic acid for 5 min at room temperature, and rinsed in water. 
Immunostaining was performed at room temperature on a Bond III automated 
immunostainer (Leica Biosystems Inc) using phospho-tau monoclonal antibody AT8 (Pierce 
Biotechnology; 1:200 for 30 minutes) and the Bond Polymer Refine detection system, which 
includes H2O2 block, EDTA-based epitope retrieval solution, rabbit anti-mouse IgG 
secondary antibody, anti-rabbit poly-HRP-IgG, DAB, and hematoxylin counterstain. 
Sections were dehydrated in a graded series of ethanol dilutions and xylene, mounted on 
coverslips, and reviewed on a Ni-U light microscope (Nikon Instruments Inc.). For 
preparation of photomicrographs, slides were imaged on an Aperio ScanScope CS whole 
slide imager (Leica) using a 20X objective, and selected fields captured using Aperio 
ImageScope v12 software.
Statistics
For all seeding experiments, cells treated with empty liposomes served as the control group. 
We used a two-tailed t-test and set significance at p <0.01. For correlational analyses, we 
performed nonparametric Spearman rank-order tests. r values represent the correlation 
between seeding in each brain region and age, MMSE, or Braak stage, with significance set 
at p <0.05.
RESULTS
Tau seeding detected across brain regions and Braak stages
Braak staging requires detection of phospho-tau pathology in discrete brain regions. To test 
for a relationship of Braak staging and tau seeding activity, we used the FRET flow 
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cytometry assay to quantify seeding activity in homogenates prepared from fresh-frozen 
brain specimens from all Braak stages, across four regions (hippocampus, frontal and 
parietal lobes, and cerebellum). We analyzed tissue from 40 individuals previously staged as 
B1, B2, or B3 based on standard histopathological criteria (Supplemental Fig.1) and 7 
additional individuals not reported to harbor tau pathology. Where possible, we analyzed 
multiple brain regions from the same subject.
All negative samples lacked seeding activity in each brain region (Fig. 1a–d). B1 samples 
consistently exhibited tau seeding activity in the hippocampus, but not in other regions (Fig. 
1a–d). B2 samples all exhibited hippocampal tau seeding (Fig. 1a), and B3 samples 
uniformly scored positive in hippocampus, frontal, and parietal lobes (Fig. 1b,c). In many 
instances, we observed seeding activity in brain regions that usually lack tau pathology, as 
monitored by histology. For example, more than half of B1 samples, in which tau pathology 
is generally limited to entorhinal cortex, had seeding activity in the hippocampus (Fig. 1a) 
and often in cortical regions (Fig. 1b,c). B2 samples, in which pathology is generally 
restricted to limbic regions, frequently exhibited seeding activity in frontal and parietal lobes 
(Fig. 1b,c). Finally, in B3 cases we even observed seeding in cerebellum, despite the fact that 
this region does not typically exhibit tau pathology (Fig. 1d). To ensure that seeding activity 
was specific to tau, we performed immunodepletion experiments on a subset of samples. 
Following incubation with either a negative control antibody (IgG) or an anti-tau antibody 
(AT8), we consistently observed a significant reduction in seeding activity when lysate was 
immunodepleted with AT8, but not IgG (Fig. 1e). Cerebellar seeding activity was depleted 
less efficiently. Possibilities for this are discussed below.
Seeding activity correlates with lower MMSE score and higher Braak stage
We next tested for correlation of seeding activity with other clinical or pathologic 
characteristics. Age did not correlate with seeding activity in any brain region (Fig. 2a–c). 
Seeding activity and cognitive status (as measured by the Mini-Mental State Examination 
(MMSE)) negatively correlated (Fig. 2d–f), particularly in the parietal lobe. Seeding activity 
correlated highly with Braak stage (Fig. 2g–i) in frontal and parietal lobes.
Seeding activity by region within individual brains
Braak and Braak first reported progressive and stereotypical neurofibrillary tangle (NFT) 
accumulation in AD brains over two decades ago [6, 7]. In recent years, numerous mouse 
studies have demonstrated that tau aggregates inoculated into the brain trigger spreading tau 
pathology [2, 12, 13, 23, 25, 27, 31, 36]. Further, we previously observed a steady increase 
in tau seeding activity in the PS19 tauopathy mouse brain, even in the absence of seed 
inoculation [21, 39]. However, it is unknown how seeding activity might vary across brain 
regions at different Braak stages within individuals. Thus, we charted the previous seeding 
data with a heat map, organized by individual. Tissue from four brain regions was not 
always available for all subjects (denoted by solid white boxes), although for every 
individual, at least two brain regions were provided. For nearly every brain in which seeding 
was detectable, we observed the highest seeding in hippocampus, next highest in neocortex, 
and lowest in cerebellum (Fig. 3). Additionally, most cases contained higher seeding activity 
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in frontal rather than parietal lobes, consistent with the original pathological characterization 
by Braak and Braak [6].
Seeding detects pathology more sensitively than biochemistry
Accumulation of detergent-insoluble tau is associated with progressive pathology. Thus, we 
tested the relative sensitivity of solubility analysis of tau vs. its seeding activity. We 
extracted total, soluble, and sarkosyl-insoluble fractions from each brain sample [9] and 
measured tau levels using an ultra-sensitive ELISA developed by the Peter Davies laboratory 
[1]. We detected tau in all total (Fig. 4a) and soluble (Fig. 4b) fractions, regardless of brain 
region or Braak stage, whereas we observed a more variable presence of detergent-insoluble 
tau (Fig. 4c), which correlated with the reported Braak stage: minimal in B1, moderate in 
B2, and extensive in B3, excluding cerebellum, which lacked insoluble tau as measured by 
ELISA.
We then analyzed each biochemical fraction for seeding activity. We observed seeding in 
many total (Fig. 4d), soluble (Fig. 4e), and insoluble (Fig. 4f) fractions with the exception of 
negative control subjects, but no correlation with tau levels. Importantly, a large number of 
B1, B2, or B3 samples had no apparent insoluble tau as characterized by ELISA, yet they 
exhibited strong seeding activity (Fig. 4f, highlighted in yellow). Overall, we detected 
seeding activity in 82 of 104 insoluble sample fractions. Of note, 18 of these 82 (~22%) 
initially scored negative when seeding was first evaluated from the total fraction. This 
indicates that when the total lysate scores negative it is still possible to enrich seeding 
activity using detergent fractionation. In no instance did we detect seeding in the total 
fraction but not the insoluble fraction. We conclude that tau seeding activity does not 
correlate with total tau protein level, and that the FRET seeding assay is highly sensitive for 
the detection of tau aggregate seeds.
DISCUSSION
Tau pathology in AD develops progressively in regions of brain with known synaptic 
connectivity, and prion-like transcellular propagation of seeds has been proposed to explain 
this observation [4, 11, 21, 31]. This model makes a strong prediction that seeding activity 
should anticipate subsequent development of neuropathology. To test this idea, we quantified 
tau seeding activity in fresh-frozen brain samples derived from 40 individuals at different 
Braak stages, across four brain regions. We detected proteopathic tau seeding activity across 
specimens more extensively than is typically observed by histopathology or biochemical 
studies alone. In particular, we observed robust seeding activity in many hippocampal 
samples from B1 brains and in many parietal and frontal lobe samples from B2 brains. In a 
subset of B3 brains, we even observed seeding activity within the cerebellum, which 
typically has no detectable tau pathology based on immunohistochemistry. Importantly, 
despite trying several anti-tau antibodies in addition to AT8, together or in sequence, we 
never achieved full depletion of cerebellar seeding activity. Despite the fact that we have 
never observed cross-seeding events between other amyloids and tau, we conclude that some 
seeding activity in the cerebellum might represent a non-tau factor, or tau species for which 
the epitopes are masked or unavailable due to posttranslational modifications, protein 
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interactions, or distinct strain structure. Taken together, however, our findings support the 
model of transcellular propagation of tau pathology, and suggest that seed detection might 
augment standard histopathological analysis.
Seed detection as a quantitative adjunct for neuropathology
Pathological assessment of NFTs was first described by Braak and Braak several decades 
ago [6, 7], and their AT8 staining protocols are now the gold standard for pathological 
characterization of AD. Although staining methods are well established and the progression 
of phospho-tau pathology is predictable, the analysis of a brain still requires the subjective 
impression of a qualified neuropathologist. While the recently revised grouping of Braak 
stages described by the National Institute on Aging and the Alzheimer’s Association [22] 
may help to standardize diagnosis, Braak staging by immunohistochemistry remains an 
imperfect metric of tau pathology.
The FRET flow cytometry assay we have previously described sensitively and specifically 
quantifies tau seeding activity in biological samples [17, 21]. We have never observed non-
specific seeding of tau by heterologous fibrillar species, suggesting that it is both sensitive 
and specific [21, 31]. The assay is user-friendly and relatively high-throughput, with a 
continuous signal spectrum. It requires appropriate positive and negative controls, along 
with a dedicated flow cytometer and an experienced operator, which may limit its broad 
applicability.
With this assay we detected tau seeding activity in human lysates across multiple brain 
regions and Braak stages. Seeding activity correlates with Braak staging, but appears to be 
more sensitive to the presence of pathological tau. This suggests that the seeding assay could 
complement standard histopathology. Quantification of seeding activity in multiple regions 
or sub-regions of brain might reveal new aspects of tauopathy that cannot be visualized by 
immunohistochemistry or biochemistry, especially early in disease.
The tau seeding assay requires relatively small amounts of brain tissue (<100 µg), which 
may be beneficial when samples are limited. In this study, we used fresh-frozen tissue, 
which precluded simultaneous analysis of the same brain region by histopathology. 
However, future work will determine the feasibility of using fixed tissue, which we expect 
will be compatible given the resistance of amyloid beta and alpha synuclein seeds to 
formaldehyde fixation [14, 33]. If compatible with the tau seeding assay, fixed tissue 
analysis could open up important possibilities for combining it with neuropathological 
analysis in the same region. While evaluation of seeding activity in one small sample may 
not accurately represent the entire brain structure, its relatively high throughput nature 
enables multiple samples to be tested across brain regions without much additional labor. In 
combination with current AT8 staining protocols, we anticipate that the two metrics together 
might augment the detection, quantification, and characterization of tau pathology.
Seeding as an early marker of pathology
We observed that seeding activity generally correlates with the characteristic phospho-tau 
staining patterns described by Braak staging. However, numerous tissue samples exhibited 
obvious seeding activity prior to when Braak staging would predict tau pathology. For 
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example, according to B1 staging guidelines, phospho-tau is restricted to entorhinal cortex, 
yet we observed seeding activity in >50% of B1 hippocampal homogenates. Similarly, in B2 
brains, where tau pathology is limited to the entorhinal or limbic systems, we consistently 
measured tau seeding activity in parietal and frontal lobes. In B3 brains we observed seeding 
activity in every hippocampal and cortical sample tested, and even in occasional cerebellar 
samples, which typically lack phospho-tau histopathology. Immunodepletion studies along 
with previously-published material [31] suggest that the seeding activity quantified here is 
tau-specific and not the result of cross-seeding from another pathological source. In addition 
to standard histological patterns of tau pathology, seeding activity also proved to be more 
sensitive than standard biochemical analysis of tau in brain lysates. In numerous cases 
samples had no detectable insoluble tau based on an ultra-sensitive ELISA (detection level 
of ~24 pg/mL tau [1]), but scored positive with the FRET flow cytometry assay. Thus, we 
anticipate that the seeding assay might also augment standard biochemical analyses of 
insoluble (i.e. pathological) tau.
We previously observed that seeding activity is the earliest marker of disease in the PS19 
tauopathy mouse model, as it appears months before multiple immunohistochemical markers 
score positive, including AT8, PG5, and MC1 [21]. Because the current work did not 
evaluate human tissue specimens in parallel for histopathology and seeding, as was done in 
the mouse study, we cannot conclude with certainty that seeding activity precedes deposition 
of phospho-tau in these human brain specimens. This must await simultaneous comparison 
with both methods of very closely spaced sub-regions of brain. Seeding activity that is 
detected prior to histopathological abnormality could be due to the presence of very small 
tau assemblies that are seed-competent (trimer or above [26]), but that may not feature 
abundant phosphorylation. Alternatively, the seeding species may be below the threshold of 
detection of any type of immunohistochemistry. Regardless, we hope future work will be 
able to determine the significance of seeding activity observed in the absence of 
histopathological tau abnormalities.
Tau seeding and the prion hypothesis
There is no evidence of inadvertent transmission of tau pathology between individuals. 
Nonetheless, in experimental systems, we and others have observed that tau acts as a prion 
in many other respects [11, 12, 31]. It is impossible to know whether trans-cellular 
propagation underlies progression of disease in patients until we have an effective therapy 
designed to block this process. However, the hypothesis that proteopathic seeds cause 
pathology clearly predicts that seeding activity should develop prior to the occurrence of 
neuropathology that is visible by stains for macromolecular protein assemblies. While this 
study has a critical limitation in that the fresh-frozen tissues studied with the FRET assay are 
not the same as those that were used for Braak staging of brains, the early and widespread 
detection of seeding is consistent with the prion model to explain progressive accumulation 
of tau pathology and neurological dysfunction in AD. We hope that future studies that 
employ a similar multimodal assessment of human tissues will clarify these initial 
observations.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Tau seeding activity is present in multiple brain regions and increases with Braak stage
20 µg of clarified human brain lysate was transduced into Tau-RD-P301S CFP/YFP 
biosensor cells, which were harvested for FRET flow cytometry after 24 hr. Hippocampus 
(a), Frontal Lobe (b), and Parietal Lobe (c) all consistently scored positive for seeding from 
B3 brains (represented by red squares). B2 brains (represented by blue triangles) also 
demonstrated strong hippocampal seeding activity and moderate cortical seeding. B1 
subjects (represented by green circles) consistently showed hippocampal seeding activity. 
Cerebellum (d) contained seeding activity in a few B3 samples. Error bars denote SEM, and 
dashed lines represent threshold for significant seeding (p <0.01), as compared to cells 
treated with empty liposomes. Standardized seeding activity represents the fold change in 
signal over negative control biosensor cells.
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Figure 2. Correlation of tau seeding with MMSE and Braak stage
We evaluated seeding activity with subject age (a–c), MMSE (d–f) and Braak stage (g–i) 
using nonparametric Spearman correlational analyses. Age and seeding activity did not 
correlate; MMSE and seeding activity negatively correlated; and Braak stage and seeding 
activity positively correlated (p <0.05).
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Figure 3. Seeding activity determined by region in individuals
Relative tau seeding activity was assessed in brain regions within the same individuals. Each 
row represents an individual subject (n=47), and each column represents a specific brain 
region. Samples not provided for a region are colored with grey dots. Representative seeding 
values are shaded light to dark blue with the latter corresponding to highest seeding activity. 
Seeding activity is highest in hippocampus and increases with Braak stage.
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Figure 4. Biochemical characterization of brain homogenates
Brain lysates were biochemically extracted, and subsequent fractions were quantified using 
ELISA (a–c) and FRET flow cytometry (d–f). All samples contained total (a) and soluble (b) 
tau. Insoluble tau (c) was measurable in only a subset of samples. Seeding activity was 
present variably in all total (d) or soluble (e) fractions, and was present in almost all 
insoluble fractions (f), even those that did not score positive with ELISA. The yellow box (f) 
highlights 41 samples that were ELISA-negative and seed-positive.
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